Advances and issues in mantle cell lymphoma research: Report of the 2014 Mantle Cell Lymphoma Consortium Workshop

Brad S. Kahl*, Leo I. Gordon, Martin Dreyling, Randy D. Gascoyne, Eduardo M. Sotomayor

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma characterized by the t(11;14) chromosomal translocation and cyclin D1 over-expression. A biologically and clinically heterogeneous lymphoma, MCL, remains clinically challenging, with no proven curative therapy and no established standard of care. However, there have been considerable advances in the last several years in the treatment and understanding of MCL with the FDA approval of lenalidomide and ibrutinib, the development of other potentially active novel agents and the identification of recurrent mutations through new genomic sequencing approaches that may contribute to the biology of MCL and to therapeutic resistance. At the Lymphoma Research Foundation's 11th MCL Workshop, researchers gathered to discuss recent studies and current issues related to the biology of MCL, novel therapeutic targets and new treatment strategies. The presentations are summarized in this manuscript, which is intended to highlight areas of active investigation and identify topics for future research.

Original languageEnglish (US)
Pages (from-to)2505-2511
Number of pages7
JournalLeukemia and Lymphoma
Issue number9
StatePublished - Sep 2 2015


  • Lymphoma and Hodgkin's disease
  • immunotherapy
  • marrow and stem cell transplantation clinical results
  • pharmacotherapeutics

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Advances and issues in mantle cell lymphoma research: Report of the 2014 Mantle Cell Lymphoma Consortium Workshop'. Together they form a unique fingerprint.

Cite this